NEKTAR THERAPEUTICSNKTREarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, e...
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| TCG Crossover GP II, LLC | 9.90% | 20.0M | — | 2024-03-15 |
| BlackRock, Inc. | 8.70% | 16.0M | flat | 2024-11-08 |
| Deep Track Capital, LP | 8.65% | 15.9M | ▼ -1.00pp | 2024-11-14 |
| The Vanguard Group | 6.31% | 12.0M | ▼ -0.06pp | 2024-02-13 |
| Eventide Asset Management, LLC | 5.11% | 9.4M | — | 2024-11-14 |
| PRIMECAP Management Company | 4.31% | 8.1M | — | 2023-07-07 |
| Citadel Advisors LLC | 3.00% | 190.8M | ▼ -1.00pp | 2024-02-14 |
| OF ABOVE PERSONS | 2.90% | 5.5M | — | 2023-07-10 |
| NOS. OF ABOVE PERSONS | 0.00% | 640.3M | ▼ -9.80pp | 2024-02-14 |
Insider Transactions
Net 90d: −$44.0K · buys $0 / sells $44.0KRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-02-18 | ROBIN HOWARD W | President & CEO | Sell (open market) | 423 | $73.00 | $30.9K |
| 2026-02-18 | Jonathan Zalevsky | Chief R&D Officer | Sell (open market) | 180 | $73.00 | $13.1K |
1–2 of 2